CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- 4 Open-market buy Chief Financial Officer bought 5,500 shares at $26.10 ($143,550)
- 8-K Event Regulation FD disclosure · Other events
- 4 Planned sale Chief Executive Officer sold 4,522 shares at an average $31.68 ($143,273)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Operating Officer sold 10,000 shares at an average $33.19 ($331,856)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Executive Officer sold 2,210 shares at an average $39.17 ($86,565)
- 4 Planned sale Chief Executive Officer sold 8,210 shares at an average $45.61 ($374,498)
- 4 Planned sale Chief Executive Officer sold 18,921 shares at $49.57 ($937,957)
- 4 Planned sale Chief Development Officer sold 50,160 shares at an average $50.47 ($2,531,582)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale Chief Development Officer sold 404 shares at $49.90 ($20,160)
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Planned sale Chief Executive Officer sold 51,499 shares at an average $47.25 ($2,433,176)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
Page 2 of 13 · 253 filings